- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | FDA rejects Zealand Pharma's GLP-2 analog in rare bowel disease | ||
| Do | Merck's HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies | ||
| Do | FDA elevates Boston Scientific cryoablation correction effort following four deaths | ||
| Do | Omeros antibody improves overall survival by 68% in rare condition, new analysis finds | ||
| Do | VC firm pens $608M biobucks deal to redirect NGM's MASH drug to rare disease | ||
| Do | Regeneron anticoagulant bests enoxaparin, matches Eliquis in phase 2 trial | ||
| Do | Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors | ||
| Do | Lawsuit accuses Applied Therapeutics of misleading investors before FDA rejection | ||
| Do | Astellas pays Sangamo $20M upfront to improve neurological gene therapy capabilities | ||
| Do | Former Seagen CEO's biotech raises $140M series A to ready PD1/VEGFR2 antibody for clinic | ||
| Do | BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects | ||
| Do | Roche reports failure of Prothena-partnered Parkinson's prospect in phase 2b, but highlights positives | ||
| Mi | XGEN Venture closes $190M fund with plans to invest in early-stage biotech, medtech firms | ||
| Mi | Labcorp launches bird flu test amid first severe case in the US | ||
| Mi | Ring Therapeutics lays off just under half of staff in 2nd wave of cuts this year, CEO set to step down | ||
| Mi | Alphabet spinoff SandboxAQ raises $300M fund for 'next wave of AI' | ||
| Mi | Merck KGaA's MilliporeSigma absorbs Dutch organoid maker HUB Organoids | ||
| Mi | Novartis, BioAge take on age-related diseases in $550M pact | ||
| Mi | Fibrosis-focused Tvardi to go public via merger with cash-strapped Cara | ||
| Mi | Roche to bring mass spec to routine labs with new cobas system's European approval | ||
| Mi | Holoclara wriggles roundworm-derived molecule into phase 1, burrowing into eosinophilic esophagitis | ||
| Mi | Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug | ||
| Mi | Novo Nordisk taps Photys for $186M cardiometabolic collab | ||
| Mi | Aurion's regenerative eye disease med improves vision in phase 1/2 trial | ||
| Mi | Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
